<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192332</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00974</org_study_id>
    <nct_id>NCT03192332</nct_id>
  </id_info>
  <brief_title>Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke</brief_title>
  <acronym>SWIFT DIRECT</acronym>
  <official_title>Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has&#xD;
      been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years. Whether IV&#xD;
      t-PA prior to endovascular clot retrieval is beneficial for AIS patients with a proximal&#xD;
      vessel occlusion in the anterior circulation has currently become a matter of debate and is a&#xD;
      relevant unanswered question in clinical practice.&#xD;
&#xD;
      The main objective is to determine whether subjects experiencing an AIS due to large&#xD;
      intracranial vessel occlusion in the anterior circulation will have non-inferior functional&#xD;
      outcome at 90 days when treated with direct mechanical thrombectomy (MT) compared to subjects&#xD;
      treated with combined IV t-PA and MT.&#xD;
&#xD;
      The secondary objectives are to study causes of mortality, dependency and quality of life in&#xD;
      these AIS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has&#xD;
      been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years. Since&#xD;
      December 2014 a new era in acute stroke treatment has begun: randomized controlled studies&#xD;
      have consistently shown that endovascular clot retrieval in addition to best medical&#xD;
      treatment (± IV t-PA) improves outcome in acute anterior circulation stroke patients with&#xD;
      proximal vessel occlusion compared to best medical treatment alone. Whether pre-treatment&#xD;
      with IV t-PA prior to endovascular clot retrieval is beneficial has now become a matter of&#xD;
      debate. A pooled analysis of 5 RCTs (MR CLEAN, SWIFT-PRIME, EXTEND IA, ESCAPE and REVASCAT)&#xD;
      suggested that the treatment effect size of MT does not differ between patients receiving&#xD;
      intravenous thrombolysis (IVT) and those treated with MT alone (p interaction: 0.4311).&#xD;
      Besides post-hoc RCT analyses, there are a myriad of observational studies reporting on rates&#xD;
      of successful reperfusion and functional outcome stratified according to IV t-PA pretreatment&#xD;
      status. There is evidence that reperfusion rates after IV t-PA in patients with occlusions of&#xD;
      the internal carotid artery and the main stem of the middle cerebral artery are low, but may&#xD;
      reach more than 80% after mechanical thrombectomy (MT). Therefore the most important factor&#xD;
      for vessel recanalization, which is linked with favorable outcome, is MT.&#xD;
&#xD;
      No randomized controlled trial has ever assessed whether direct MT in patients with AIS is&#xD;
      equally effective as MT in combination with IV t-PA (bridging thrombolysis). In a&#xD;
      patient-level pooled analysis of five randomized controlled studies (HERMES collaboration)&#xD;
      similar rates of functional independence and mortality at 90 days were observed between&#xD;
      patients who received IV t-PA+MT and those who received direct MT. However, patients in the&#xD;
      direct MT group had contraindications for IV t-PA. Two larger studies based on registries&#xD;
      compared the outcome of patients after bridging thrombolysis with direct MT in patients&#xD;
      eligible for IV t-PA. In both studies, the outcome of patients after bridging thrombolysis&#xD;
      and direct MT was similar. For these reasons the investigators hypothesize that immediate and&#xD;
      direct MT is not inferior and might even be superior to bridging thrombolysis in patients&#xD;
      directly referred to a stroke center with rapid access to endovascular procedures.&#xD;
&#xD;
      In this trial all commercially available stent-retriever revascularization devices&#xD;
      manufactured by Medtronic (e.g. Solitaire™) will be used as tool for direct MT. The&#xD;
      investigators aim to provide conclusive information on the efficacy and safety of direct MT,&#xD;
      in comparison with bridging thrombolysis.&#xD;
&#xD;
      If direct MT in patients with AIS would not be inferior to bridging thrombolysis, the&#xD;
      organization of acute stroke management would change essentially. Direct MT would then be the&#xD;
      therapy of choice in stroke centers with endovascular facilities. Furthermore, this trial&#xD;
      could have an impact on healthcare guidelines and costs. However, this trial does not address&#xD;
      the question, whether patients arriving in stroke units with no endovascular facilities&#xD;
      should be pre-treated with IV t-PA or whether they should directly be referred to stroke&#xD;
      centers with endovascular facilities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open label, blinded endpoint (PROBE)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessment of the primary outcome will be performed by an independent and blinded person.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Score in modified Rankin Scale (mRS)</measure>
    <time_frame>90 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) shift analysis</measure>
    <time_frame>day 0 and 90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Score Scale (NIHSS)</measure>
    <time_frame>day 0 and day 1 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Cerebral Infarction (TICI) scale</measure>
    <time_frame>day 0 and day 1 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>day 0 until 90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>day 1 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by questionnaire</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall costs incurred during hospitalisation</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Direct mechanical thrombectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined intravenous thrombolysis and mechanical thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent-retriever thrombectomy with revascularization device of the Solitaire™ type</intervention_name>
    <description>Mechanical thrombectomy with a stent-retriever revascularization device</description>
    <arm_group_label>Combined intravenous thrombolysis and mechanical thrombectomy</arm_group_label>
    <arm_group_label>Direct mechanical thrombectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)</intervention_name>
    <description>Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.</description>
    <arm_group_label>Combined intravenous thrombolysis and mechanical thrombectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent as documented by signature&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. Clinical signs consistent with an acute ischemic stroke&#xD;
&#xD;
          4. Neurological deficit with a NIHSS of ≥ 5 and &lt; 30 (deficits judged to be clearly&#xD;
             disabling at presentation)&#xD;
&#xD;
          5. Patient is eligible for intravenous thrombolysis&#xD;
&#xD;
          6. Patient is eligible for endovascular treatment&#xD;
&#xD;
          7. Randomization no later than 4 hours 15 minutes after stroke symptom onset and&#xD;
             initiation of IV t-PA must be started within 4 hours 30 minutes of stroke symptoms&#xD;
             onset (onset time is measured from the time when the subject was last seen well)&#xD;
&#xD;
          8. Occlusion (TICI 0-1) of the intracranial internal carotid artery (ICA), the M1 segment&#xD;
             of the middle cerebral artery (MCA), or both confirmed by CT or MR angiography,&#xD;
             accessible for MT&#xD;
&#xD;
          9. Core-infarct volume of Alberta Stroke Program Early CT Score (ASPECTS) greater than or&#xD;
             equal to 4 (≥ 4) based on baseline CT or MR imaging (MRI) (a region has to have&#xD;
             diffusion abnormality in 20% or more of its volume to be considered MR-ASPECTS&#xD;
             positive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute intracranial hemorrhage&#xD;
&#xD;
          2. Any contraindication for IV t-PA&#xD;
&#xD;
          3. Pre-treatment with IV t-PA&#xD;
&#xD;
          4. In-hospital stroke&#xD;
&#xD;
          5. Pregnancy or lactating women. A negative pregnancy test before randomization is&#xD;
             required for all women with child-bearing potential.&#xD;
&#xD;
          6. Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals,&#xD;
             or their alloys&#xD;
&#xD;
          7. Known current participation in a clinical trial (investigational drug or medical&#xD;
             device)&#xD;
&#xD;
          8. Renal insufficiency as defined by a serum creatinine &gt; 2.0 mg/dl (or 176.8 µmol/l) or&#xD;
             glomerular filtration rate (GFR) &lt; 30 mL/min or requirement for hemodialysis or&#xD;
             peritoneal dialysis&#xD;
&#xD;
          9. Severe comorbid condition with life expectancy less than 90 days at baseline&#xD;
&#xD;
         10. Known advanced dementia or significant pre-stroke disability (mRS score of ≥2)&#xD;
&#xD;
         11. Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living&#xD;
             abroad)&#xD;
&#xD;
         12. Comorbid disease or condition that would confound the neurological and functional&#xD;
             evaluations or compromise survival or ability to complete follow-up assessments.&#xD;
&#xD;
         13. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol&#xD;
             (defined as regular or daily consumption of more than four alcoholic drinks per day).&#xD;
&#xD;
         14. Known history of arterial tortuosity, pre-existing stent, other arterial disease&#xD;
             and/or known disease at the femoral access site that would prevent the device from&#xD;
             reaching the target vessel and/or preclude safe recovery after MT&#xD;
&#xD;
         15. Radiological confirmed evidence of mass effect or intracranial tumor (except small&#xD;
             meningioma)&#xD;
&#xD;
         16. Radiological confirmed evidence of cerebral vasculitis&#xD;
&#xD;
         17. CTA or MRA evidence of carotid artery dissection&#xD;
&#xD;
         18. Evidence of additional distal intracranial vessel occlusion in another territory (i.e.&#xD;
             A2 segment of anterior cerebral artery or M3, M4 segment of MCA) on initial NCCT/MRI&#xD;
             or CTA/MRA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urs Fischer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurology, Inselspital Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Gralla, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neuroradiology, Inselspital Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keppler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mc Gill University</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital, University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cavale Blanche CHU Brest</name>
      <address>
        <city>Brest</city>
        <state>Finistère</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy-de-Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHU Paris Psychiatrie et Neurosciences, Sainte Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen Normandie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Île De France</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, Universität Heidelber</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück GmbH</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus GmbH Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Vest GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Ospedale Civo of Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Centre hospitalier universitaire vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève - HUG</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neuroradiology, UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.swift-direct.com/</url>
    <description>Trial Website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravenous thrombolysis</keyword>
  <keyword>Endovascular treatment</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Bridging thrombolysis</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

